Publications en collaboration avec des chercheurs de Yale University (28)

2024

  1. Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review

    Seminars in Thrombosis and Hemostasis, Vol. 50, Núm. 6, pp. 851-865

  2. Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications

    Seminars in Thrombosis and Hemostasis, Vol. 50, Núm. 5, pp. 773-789

  3. Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease

    Nature Reviews Cardiology, Vol. 21, Núm. 8, pp. 574-592

  4. When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 83, Núm. 3, pp. 444-465

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial

    Thrombosis and haemostasis, Vol. 123, Núm. 7, pp. 723-733

  3. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials

    Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 16-30

  4. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  5. Sex-Related Differences in Patient Characteristics, Risk Factors, and Symptomatology in Older Adults with Pulmonary Embolism: Findings from the SERIOUS-PE Study

    Seminars in Thrombosis and Hemostasis, Vol. 49, Núm. 7, pp. 725-735

2022

  1. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial

    The BMJ, Vol. 376

  2. Catheter-Directed Thrombolysis vs Anticoagulation in Patients with Acute Intermediate-High-risk Pulmonary Embolism: The CANARY Randomized Clinical Trial

    JAMA Cardiology, Vol. 7, Núm. 12, pp. 1189-1197

  3. Developing Validated Tools to Identify Pulmonary Embolism in Electronic Databases: Rationale and Design of the PE-EHR+ Study

    Thrombosis and Haemostasis, Vol. 123, Núm. 6, pp. 649-662

  4. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes

    European Journal of Internal Medicine, Vol. 103, pp. 76-83

  5. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review

    JAMA Cardiology, Vol. 7, Núm. 7, pp. 747-759

  6. Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study

    Thrombosis Research, Vol. 214, pp. 122-131

  7. Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment

    Contemporary Clinical Trials, Vol. 115

2021

  1. Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19

    Journal of the American College of Cardiology, Vol. 78, Núm. 4, pp. 408-411

  2. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality among Patients with COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 325, Núm. 16, pp. 1620-1630

  3. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial

    Thrombosis and Haemostasis, Vol. 122, Núm. 1, pp. 131-141

  4. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 78, Núm. 16, pp. 1635-1654